Miya K, Saji S, Furuta T, Tanemura H, Azuma S, Umemoto T, Kunieda K, Takao H, Sugiyama Y, Kawai M
2nd Dept. of Surgery, Gifu University School of Medicine.
Gan To Kagaku Ryoho. 1991 Aug;18(11):1992-5.
In order to improve therapeutic efficacy for metastatic liver cancer, intermittent transarterial administration of BRM in combination with anticancer drugs was performed by use of reservoir apparatus. A total of 22 patients (12 cases of gastric cancer, 6 of colon cancer, 2 of pancreas cancer, 1 of gall bladder cancer and 1 of biliary tract carcinoid) were treated according to the following schedule: both 10 mg of ADM (or MMC) and 0.5 KE (or 1.0 KE) of OK-432 were administered on day 1 and 40 x 10(4) JRU of recombinant interleukin 2 (r-IL 2) on day 4, 7 and 11. The treatment was repeated as many times as possible. In terms of direct antitumor effect and decrease of tumor marker, the response rate was 43% (6 cases out of 14) and 75% (9 cases out of 12), respectively. As for performance status, improvement, no change and deterioration were seen in 4 cases, 8 cases and 3 cases, respectively. Even though 13 patients died, 8 of them survived more than 300 days. In the case of gastric cancer patients with liver metastasis, 50% survival time of 12 cases was 334 days, while that of 30 cases, who were administered anticancer drugs only systemically, was 144 days. In 3 cases the decrease in the size of tumors located in both liver and the other metastases also was seen. Every case developed high grade fever, but an antifebrile was effective. Otherwise severe side effects were not seen. These results indicated that intermittent arterial infusion immunochemotherapy was feasible for the treatment of metastatic liver cancer.
为提高转移性肝癌的治疗效果，采用储液器装置进行BRM与抗癌药物联合的间歇性动脉内给药。共22例患者（胃癌12例、结肠癌6例、胰腺癌2例、胆囊癌1例、胆道类癌1例）按以下方案治疗：第1天和第4天分别给予阿霉素（或丝裂霉素）10mg及OK - 432 0.5KE（或1.0KE），第4、7和11天给予重组白细胞介素2（r - IL 2）40×10⁴JRU。治疗尽可能多次重复。就直接抗肿瘤作用和肿瘤标志物下降情况而言，有效率分别为43%（14例中的6例）和75%（12例中的9例）。关于身体状况，改善、无变化和恶化分别见于4例、8例和3例。尽管有13例患者死亡，但其中8例存活超过300天。对于有肝转移的胃癌患者，12例的50%生存时间为334天，而仅全身给予抗癌药物的30例患者的50%生存时间为144天。在3例患者中还可见到肝脏及其他转移灶处肿瘤大小减小。每例患者均出现高热，但退热药有效。此外未见到严重副作用。这些结果表明间歇性动脉灌注免疫化疗治疗转移性肝癌是可行的。
